Precision Medicine in Oncology®

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Over the past several years, several new approaches to treatment have prolonged and improved quality of life for patients with metastases.

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

While competition is the hallmark of the powerhouse sports teams of the Big Ten Conference, collaboration will be the key for a research initiative recently launched by cancer centers at most of the same universities.

An interview with Rakesh K. Jain, PhD, a cancer researcher focused on pathophysiology who helped establish the role of the tumor microenvironment in the treatment of cancer.

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

An interview with Andrew Scott, MB,BS, MD, whose work has led to the successful translation of novel potential cancer therapeutics into clinical development.

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.